NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

542.45 7.00 (1.31%)

28.54% Gain from 52W Low

498.7K NSE+BSE Volume

NSE 12 Nov, 2025 3:31 PM (IST)

13,163.6

Market Cap

High in industry

1.4

Beta 1Year

Very High Volatility

Board Meeting

The next board meeting for Granules India Ltd. is on 13 Nov 2025 for the purpose of Quarterly Results See details

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Search Inside the pdf :

Granules India Ltd.

18 Sep 2025

542.45

1.31%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...

Granules India Ltd. has gained 23.03% in the last 6 Months

Granules India Ltd.

22 Aug 2025

542.45

1.31%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.

Granules India Ltd. has gained 23.03% in the last 6 Months

Granules India Ltd.

06 Jun 2025

542.45

1.31%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....

Granules India Ltd. has gained 23.13% in the last 3 Months

Granules India Ltd.

28 May 2025

542.45

1.31%

Broadly in-line quarter; margin resilience led by FDF

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.

Granules India Ltd. is trading below its 30 day SMA of 558.2

Granules India Ltd.

17 Feb 2025

542.45

1.31%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Mutual Funds have decreased holdings from 12.24% to 6.54% in Sep 2025 qtr

Granules India Ltd.

25 Jan 2025

542.45

1.31%

Finished dosages remain the key earnings driver

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.

Granules India Ltd. has an average target of 587.67 from 3 brokers.

Granules India Ltd.

06 Nov 2024

542.45

1.31%

Plants Resuming Operations and Upcoming Product Launches

Buy: Granules India Ltd.

Target

Sharekhan

Revenues stood at Rs. 957 crore, falling 19% y-o-y and 18% q-o-q, falling 5% short of our estimates.

Number of MF schemes decreased from 28 to 17 in Sep 2025 qtr

Granules India Ltd.

12 Sep 2024, 12:00AM

542.45

1.31%

Gagillapur site under a cloud

Buy: Granules India Ltd.

Motilal Oswal

Granules India (GRAN) was issued a Form 483 with six observations for its Gagillapur site after a recent USFDA inspection.

Granules India Ltd. has gained 23.03% in the last 6 Months

Granules India Ltd.

16 Aug 2024

542.45

1.31%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. has an average target of 587.67 from 3 brokers.

Granules India Ltd.

31 Jul 2024

542.45

1.31%

FD and low base doubled earnings YoY

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) posted in-line revenue in 1QFY25. However, it delivered better-than-estimated 1QFY25 EBITDA/PAT led by the increased share of formulation sales.

Granules India Ltd. has an average target of 587.67 from 3 brokers.

Is Granules India Ltd. worth buying?

866 Votes:

Buy 84.06%

Sell 10.16%

Hold 5.77%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf